Logimax, which contains metoprolol, is a medication indicated for addressing specific concerns within the cardiovascular system.

The active ingredient is indicated for use in treating hypertension (high blood pressure); for the long-term care of angina pectoris (chest pain); and is also used in patient care after certain cardiac events. The medication may also be used for addressing specific types of irregular heart rhythm (arrhythmia), and in the management of symptoms related to migraines or an overactive thyroid (thyrotoxicosis).

The therapeutic effect of the medication contributes to the management of related symptoms. The medication is intended to support patient stability and comfort in managing specific cardiovascular concerns.

---

Quick Fact: Support for Chest Discomfort

The active ingredient can be a component in managing chest discomfort associated with angina.

Logimax (Felodipine/Metoprolol Succinate) is restricted to specific patient populations as defined by regulatory bodies. The medication is primarily intended for adults but is not recommended for the pediatric population (children and adolescents) due to a lack of established safety and efficacy data.

Contraindicated Populations

Use of Logimax is absolutely prohibited (contraindicated) for individuals with the following conditions:

• Acute Cardiac Conditions: Cardiogenic shock, unstable or decompensated cardiac failure, or second/third-degree Atrioventricular (AV) block (without a pacemaker).
• Rhythm and Pressure: Severe symptomatic bradycardia (low heart rate) or profound hypotension.
• Hypersensitivity: Known allergy to the active ingredients (Felodipine, Metoprolol Succinate), other beta-blockers, or other dihydropyridines.
• Metabolic: Severe acute states of metabolic acidosis.

Restricted and Conditional Use

Some populations require strict precautions or dose limitations as defined in the official labeling:

• Organ Impairment: Patients with serious impairment of liver function must be restricted to the lowest available dose strength.
• Pregnancy and Lactation: The medication is contraindicated during pregnancy in some regulatory documents, and its use is generally not recommended or requires caution during breastfeeding.
• Comorbidities: Caution is required for patients with diabetes (due to masked hypoglycemia symptoms) and those with severe bronchospastic disease or peripheral arterial disease.

Interactions with other medicines and products

This section summarizes interactions for Logimax (Felodipine/Metoprolol Succinate) as documented in official government regulatory information.

---

Contraindicated and Restricted Combinations

The intravenous administration of Verapamil is strictly prohibited due to the risk of severe additive depressant effects on the heart. Furthermore, doses higher than 5 mg/ 47.5 mg are not recommended for patients with very severely impaired hepatic function due to altered drug clearance.

---

Pharmacokinetic and Exposure Interactions

The Logimax profile is influenced by drug metabolism via the Cytochrome P450 system:

• Felodipine (CYP3A4 substrate): Exposure may decrease with inducers such as Rifampicin, Phenytoin, and St. John's Wort, and may increase with inhibitors like Grapefruit Juice.
• Metoprolol (CYP2D6 substrate): Exposure may increase with potent CYP2D6 inhibitors, including certain antidepressants (e.g., Fluoxetine, Paroxetine) and antiarrhythmics (e.g., Quinidine).

Other agents, such as Alcohol and Hydralazine, are also documented to raise Metoprolol plasma concentrations.

---

Pharmacodynamic and Procedural Interactions

Logimax may have additive effects with other heart-acting agents, including Digitalis, other beta-blockers, and some Calcium Channel Blockers (e.g., Diltiazem). If Clonidine therapy is to be discontinued, the Logimax component must be withdrawn several days beforehand to prevent the risk of rebound hypertension, as specified in prescribing documents.

How Logimax Works: Pharmacodynamic Mechanism

Logimax operates through two distinct, complementary mechanisms influencing two separate systems regulating physiological parameters.

1. Inhibition of Vascular Smooth Muscle Tone

Felodipine functions as an inhibitor by blocking L-type calcium channels ( CaV1.2) in arteriolar smooth muscle. This molecular action prevents the essential influx of calcium ions ( Ca^2+), which disrupts the contraction cascade and results in the relaxation of the blood vessel walls. This physiological consequence results in a decrease in Systemic Vascular Resistance (SVR).

2. Modulation of Cardiac Sympathetic Signaling

Metoprolol acts as a competitive antagonist on Beta-1 (beta1)-Adrenergic Receptors in the heart. By preventing the binding of norepinephrine and adrenaline, the drug dampens sympathetic signaling. This molecular blockade leads to the physiological effects of reduced heart rate (negative chronotropy) and decreased force of contraction, contributing to a reduction in the Cardiac Output (CO).

3. Mechanistic Synergy

The combined mechanisms act through complementary pathways, simultaneously reducing SVR and CO. Crucially, the beta1-receptor blockade prevents the reflex tachycardia that can be triggered by the vasodilation component, which supports a moderated physiological state by preventing compensatory responses.

How Logimax is Used

Logimax (Felodipine and Metoprolol Succinate) is a fixed-dose combination medication administered via the oral route as a prolonged-release tablet. This form is designed for once-daily administration, typically taken in the morning.

---

Dosing Regimens

Administration follows a standardized approach for continuous management. The usual initial dose for adults is one Logimax 5 mg/50 mg prolonged-release tablet once daily. If necessary, the dose may be increased up to a maximum of two Logimax 5 mg/50 mg tablets (total 10 mg/100 mg) once daily.

---

Administration Requirements

The prolonged-release nature of the tablet dictates specific intake requirements. The tablet must be swallowed whole with liquid; it must not be divided, crushed, or chewed. Disruption of the tablet's integrity compromises the engineered extended-release system designed to maintain consistent drug levels over a 24-hour period. Logimax may be taken without regard to meals, although administration with a light, low-fat, low-carbohydrate meal is often noted.

---

Usage in Specific Populations

Specific patient groups may require different considerations:

• Older Adults: The 5 mg/50 mg once daily strength is typically sufficient.
• Renal Function: No dose adjustment is generally required for kidney impairment.
• Hepatic Function: For patients with signs of serious liver impairment, the dose should not exceed the initial 5 mg/50 mg strength.
• Discontinuation: If treatment must be stopped, the dosage should be reduced gradually over a period of 10 to 14 days, which is a procedural step to avoid abrupt withdrawal effects.

Research Evidence / Overview of Studies for Logimax

Evidence for Use in Managing High Blood Pressure (Hypertension)

Clinical evaluation of the Logimax fixed-dose combination was primarily conducted through Randomized Controlled Trials (RCTs). These short-term studies were used in a research context to explore how outcomes related to systemic or functional imbalance, specifically high blood pressure, were measured over defined time intervals. Many of the included study populations were adult patients whose high blood pressure was not adequately controlled by taking a single medicine alone. Studies monitored changes in blood pressure readings taken at the end of the dosing period (trough) and during 24-hour periods.

The findings describe patterns observed in the studies related to the measured change in blood pressure. Research highlights changes measured during the study period when comparing the combination to a placebo or to taking only one of the active components alone. Systematic reviews compiling this evidence described the observed patterns in the measured blood pressure changes across various clinical research settings.

Evidence for Use in Managing Stable Angina Pectoris

The use of Logimax was evaluated in studies focusing on Stable Angina Pectoris, a condition characterized by fluctuating or episodic manifestations of chest pain. Research examined the combination in patients who still experienced signs of insufficient blood flow to the heart despite already being on optimal treatment with the beta-blocker component (metoprolol) alone.

Studies explored outcomes related to physical discomfort during exercise testing. Researchers monitored how patient-reported outcomes describing perceived discomfort evolved in the observed populations during structured exercise. These outcomes included the total time patients could exercise, the time until chest pain began, and physiological signs measured during the test.

Long-Term Evidence and Unanswered Research Questions

The core evidence for short-term outcomes related to blood pressure change is derived from multiple, well-controlled RCTs; however, comparative follow-up durations were limited, mostly lasting only a few months. Consequently, there is limited information for long-term outcomes, and the long-term effects on major cardiovascular outcomes are not fully established specifically for this combination. The existing research describes short-term changes, but the durability of the response over multiple years remains an area where data are still emerging.

A key limitation in the research is the reliance on indirect measures (called surrogate outcomes)—such as blood pressure readings and exercise test results—rather than long-term, direct measures of cardiovascular outcomes. Comparative evidence against all possible alternative therapies may be lacking, and findings were mixed or uncertain for some patient subgroups.

Key Studies & References

1. ATC Classification System: Metoprolol and other beta-blocking agents and other antihypertensives (C07FB02) – Official Classification
2. Efficacy of a fixed-dose combination of felodipine and metoprolol in patients with stable angina pectoris (FEMINA Study or similar core RCT for angina)

Common questions about Logimax (FAQ)

Q: What is Logimax and how does it work?

Logimax is a brand name for the medication felodipine, which belongs to a class of drugs called calcium channel blockers. It is primarily used to treat high blood pressure (hypertension) and chest pain (angina).

It works by blocking the entrance of calcium into the muscle cells of the heart and blood vessel walls. This causes the blood vessels to relax and widen, which lowers blood pressure and increases the supply of blood and oxygen to the heart.

---

Q: What is the usual dose of Logimax?

The dosage of Logimax is determined by your healthcare provider based on your specific medical condition and how you respond to the treatment.

• For high blood pressure, the typical starting dose is 5 mg once daily.
• The dose may be increased up to a maximum of 10 mg once daily.

Logimax is an extended-release tablet, meaning the medication is released slowly over time. You should swallow the tablet whole and do not crush or chew it.

---

Q: When is the best time to take Logimax?

Logimax is typically taken once a day.

It is best to take it at the same time each day to maintain a steady level of the medication in your body. It can be taken with or without food.

---

Q: What if I miss a dose?

If you miss a dose of Logimax, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule.

Do not take two doses at the same time to make up for a missed dose.

---

Q: What are the common side effects of Logimax?

As with all medications, Logimax can cause side effects. The most common side effects are often mild and may include:

• Headache
• Flushing (a feeling of warmth or redness in the face)
• Swelling of the ankles or feet (edema)
• Dizziness

These common side effects may become less noticeable as your body adjusts to the medication. If side effects persist or become bothersome, discuss them with your doctor.

---

Q: Can I drink grapefruit juice while taking Logimax?

No, you should not drink grapefruit juice or eat grapefruit while taking Logimax.

Grapefruit and grapefruit juice can increase the amount of Logimax absorbed into your bloodstream, which may increase the risk of side effects such as low blood pressure and dizziness. Avoid consuming any products containing grapefruit during your treatment with this medication.

Storage and Disposal Requirements

Official regulatory documents define specific conditions for the storage and disposal of Logimax (felodipine/metoprolol succinate) prolonged-release tablets to maintain product stability and ensure safety.

---

Storage Conditions

• Temperature: Store at a temperature not exceeding 30°C.
• Environmental Protection: The tablets must be kept in the original container/package and require explicit protection from moisture and light.
• Child Safety: Logimax must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Logimax must be disposed of according to local requirements for pharmaceutical waste, such as medicine take-back programs. The medicine must not be discarded via wastewater or household refuse to prevent environmental contamination.